Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;146(1):15-24.
doi: 10.1007/s10549-014-2988-5. Epub 2014 May 20.

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

S Muenst  1 , A R Schaerli, F Gao, S Däster, E Trella, R A Droeser, M G Muraro, P Zajac, R Zanetti, W E Gillanders, W P Weber, S D Soysal
Affiliations

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

S Muenst et al. Breast Cancer Res Treat. 2014 Jul.

Abstract

Recent studies in multiple epithelial cancers have shown that the inhibitory receptor programmed cell death 1 (PD-1) is expressed on tumor-infiltrating lymphocytes and/or programmed death ligand 1 (PD-L1) is expressed on tumor cells, suggesting that antitumor immunity may be modulated by the PD-1/PD-L1 signaling pathway. In addition, phase 1 clinical trials with monoclonal antibodies targeting PD-1 or PD-L1 have shown promising results in several human cancers. The purpose of this study was to investigate the impact of PD-L1 expression in human breast cancer specimens. We conducted an immunohistochemistry study using a tissue microarray encompassing 650 evaluable formalin-fixed breast cancer cases with detailed clinical annotation and outcomes data. PD-L1 was expressed in 152 (23.4 %) of the 650 breast cancer specimens. Expression was significantly associated with age, tumor size, AJCC primary tumor classification, tumor grade, lymph node status, absence of ER expression, and high Ki-67 expression. In univariate analysis, PD-L1 expression was associated with a significantly worse OS. In multivariate analysis, PD-L1 expression remained an independent negative prognostic factor for OS. In subset analyses, expression of PD-L1 was associated with significantly worse OS in the luminal B HER2(-) subtype, the luminal B HER2(+) subtype, the HER2 subtype, and the basal-like subtype. This is the first study to demonstrate that PD-L1 expression is an independent negative prognostic factor in human breast cancer. This finding has important implications for the application of antibody therapies targeting the PD-1/PD-L1 signaling pathway in this disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Representative photographs of PD-L1 expression in breast cancer tissue punches a Tissue punch negative for PD-L1 expression. Magnification ×200 b Tissue punch with strong PD-L1 expression in 100 % of cells. Magnification ×200 c Same tissue punch as in b magnification ×400. d Tissue punch with strong PD-L1 expression in 40 % of cells. Magnification ×200
Fig. 2
Fig. 2
a Kaplan–Meier survival curve for overall survival depending on the expression of PD-L1 (univariate analysis) b–f Kaplan–Meier survival curves for overall survival depending on the expression of PD-L1 for the indicated breast cancer intrinsic subtypes
Fig. 3
Fig. 3
Representative flow cytometry data for PD-L1 expression in human breast cancer a stage IV breast cancer b stage I breast cancer
See this image and copyright information in PMC

Comment in

References

    1. Dermime S, et al. Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta. 2004;1704(1):11–35. - PubMed
    1. Bour-Jordan H, et al. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev. 2011;241(1):180–205. - PMC - PubMed
    1. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445–480. - PubMed
    1. Liang SC, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003;33(10):2706–2716. - PubMed
    1. Probst HC, et al. Resting dendritic cells induce peripheral CD8 + T cell tolerance through PD-1 and CTLA-4. Nat Immunol. 2005;6(3):280–286. - PubMed

Publication types

MeSH terms